New drug combo shows promise shrinking breast tumors in premenopausal women
NCT ID NCT06009627
First seen Feb 16, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This study tested whether adding a new drug called darsilide to standard hormone therapy (exemestane and goserelin) could shrink tumors more effectively in premenopausal women with a common type of breast cancer (HR positive, HER2 negative). The 119 participants had already received some chemotherapy without enough response. The main goal was to see how many women had a significant tumor shrinkage before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Jie Ge
Tianjin, Tianjin Municipality, 300000, China
Conditions
Explore the condition pages connected to this study.